For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Proteostasis Therapeutics, Inc.

USPTO Granted Patents = 24

CIPO Patents = 4

EPO Patents = 9

Trademarks = 3

Forward Citations = 99

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Benito Munoz (20 out of 55 patents)

Cecilia M Bastos (20 out of 32 patents)

Bradley Tait (15 out of 19 patents)

4. Matthew Cullen (7 out of 10 patents)

5. Megan Foley (6 out of 8 patents)

6. Daniel J Parks (6 out of 19 patents)

7. Markus Haeberlein (3 out of 9 patents)

8. Sheila Irene Hauck (3 out of 14 patents)

9. Bolin Geng (2 out of 10 patents)

10. David Kombo (2 out of 2 patents)

11. John Miller (2 out of 11 patents)

12. Robert J Chambers (1 out of 1 patent)

24 patents: Sort by Forward Citations

1. 11746098 - Proteasome activity enhancing compounds (2023-09-05),

2. 11560385 - Proteasome activity enhancing compounds (2023-01-24),

3. 11248010 - Compounds, compositions, and methods for modulating CFTR (2022-02-15),

4. 11242361 - Proteasome activity enhancing compounds (2022-02-08),

5. 11136313 - Compounds, compositions, and methods for modulating CFTR (2021-10-05),

6. 11098035 - Compounds, compositions, and methods for increasing CFTR activity (2021-08-24),

7. 11083709 - Compounds, compositions, and methods of increasing CFTR activity (2021-08-10),

8. 10899751 - Compounds, compositions, and methods for increasing CFTR activity (2021-01-26),

9. 10738040 - Compounds, compositions, and methods for increasing CFTR activity (2020-08-11),

10. 10738011 - Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis (2020-08-11),

11. 10662207 - Compounds, compositions, and methods for modulating CFTR (2020-05-26),

12. 10550106 - Compounds, compositions, and methods for modulating CFTR (2020-02-04),

13. 10548878 - Compounds, compositions, and methods of increasing CFTR activity (2020-02-04),

14. 10532996 - Proteostasis regulators (2020-01-14),

15. 10392378 - Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis (2019-08-27),

Proteostasis Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel therapies to treat diseases caused by dysfunctional protein processing, including cystic fibrosis, a genetic disorder that affects the lungs and other organs. With their unique platform, Proteostasis Therapeutics aims to restore the balance of cellular protein homeostasis, offering potential treatments for a range of diseases. To learn more about their research, pipeline, and clinical trials, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

24 Patents

#101 in Boston, MA

#800 in Massachusetts

#13,431 in US

#25,865 in the World

Boston, MA, United States of America

Proteostasis Therapeutics, Inc.

Forward Citations = 99

12 inventors:

Benito Munoz (20 out of 55 patents)

Cecilia M Bastos (20 out of 32 patents)

Bradley Tait (15 out of 19 patents)

4. Matthew Cullen (7 out of 10 patents)

5. Megan Foley (6 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…